- Home
- DXYZ vs ATAI Comparison
DXYZ vs ATAI Comparison
Compare DXYZ & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$3.88
Company Overview
Basic Information| Metric | DXYZ | ATAI |
|---|---|---|
| Founded | N/A | 2018 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DXYZ | ATAI |
|---|---|---|
| Price | $27.92 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | ★ 6.4M | 5.0M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $19.71 | $2.00 |
| 52 Week High | $72.87 | $6.73 |
Technical Indicators
Market Signals| Indicator | DXYZ | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 41.88 |
| Support Level | $25.00 | $3.44 |
| Resistance Level | $31.86 | $4.20 |
| Average True Range (ATR) | 5.31 | 0.31 |
| MACD | -2.90 | -0.07 |
| Stochastic Oscillator | 1.79 | 13.90 |
Price Performance
Historical Comparison DXYZ
ATAI
About DXYZ Destiny Tech100 Inc.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It is designed to be an investment portfolio of the Top 100 High-Growth Tech Companies.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.